GSK
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after GSK accelerated la...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical...
Latest News
1 hour ago · fool.com
GSK: 3 Key Takeaways for Long-Term InvestorsGSK started 18 phase 3 clinical trials in 2026. Specialty medicine sales grew 15% in the third quarter.
7 days ago · marketbeat.com
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory TreatmentsGSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim's Healthcare Innovation Conference.
11 days ago · reuters.com
GSK, Moderna settle patent dispute over Moderna COVID, RSV shotsGSK, Moderna settle patent dispute over Moderna COVID, RSV shots
13 days ago · nypost.com
HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEOHP, like peers Dell Technologies, Apple and Lenovo, is caught in a global memory chip squeeze.
18 days ago · seekingalpha.com
GSK: The Gas Pedal Is Still Down, But Bumps AheadDespite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventory reductions and broader RSV demand issues.
19 days ago · zacks.com
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
19 days ago · seekingalpha.com
GSK plc (GSK) Q3 2026 Earnings Call TranscriptGSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scientific Officer and Head of R&D Nina Mojas - President of Global Product Strategy Julie Brown - CFO & Executive Director David Redfern - President of Corporate Development Conference Call Participants James Gordon - Barclays Bank PLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Michael Leuchten - Jefferies LLC, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, Research Division Zain Ebrahim - JPMorgan Chase & Co, Research Division Matthew Weston - UBS Investment Bank, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Presentation Jeff McLaughlin VP of Investor Relations & Interim Head of Investor Relations Welcome, everyone, and thanks for joining GSK's Q3 2026 results.
19 days ago · marketbeat.com
What GSK (GSK) Said on Its Q3 Earnings CallGSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.
20 days ago · zacks.com
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines SalesGSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
20 days ago · benzinga.com
GSK's Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 BeatGSK Plc (NYSE:GSK) reported third-quarter adjusted earnings of $1.47 per share (54.6 pence), beating the analyst consensus estimate of $1.40.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove GSK